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Somatostatin acts via ﬁve receptors (sst1−5). We investigated if the changes in pancreatic islet sst expression in diabetic NOD
mice compared to normoglycemic mice are a consequence of hyperglycemia or the ongoing immune reaction in the pancreas.
Pancreatic islets were isolated from NOD mice precultured for 5 days and further cultured for 3 days at high or low glucose before
examined. Islets were also isolated from NOD mice and transplanted to normal or diabetic mice in a number not suﬃcient to
cure hyperglycemia. After three days, the transplants were removed and stained for sst1−5 and islet hormones. Overall, changes
in sst islet cell expression were more common in islets cultured in high glucose concentration in vitro as compared to the islet
transplantation in vivo to diabetic mice. The beta and PP cells exhibited more frequent changes in sst expression, while the alpha
and delta cells were relatively unaﬀected by the high glucose condition. Our ﬁndings suggest that the glucose level may alter sst
expressed in islets cells; however, immune mechanisms may counteract such changes in islet sst expression.
1.Introduction
Somatostatin is a peptide hormone, known to have several
biological functions, and its eﬀects are mediated via ﬁve
speciﬁc membrane-bound receptors (sst1−5). In rodents, so-
matostatin inhibits secretion of several hormones such as
insulin, glucagon, GH, TSH, and prolactin. It can also reg-
ulategastrointestinalmotility,gastricacid,andexocrinepan-
creatic secretion [1–5]. Immunohistochemical studies have
shown that all ﬁve ssts are expressed on the pancreatic islets
of rodents and that the intensity and distribution of ssts va-
ries between the subtypes, the islet cell type, and species [6–
8].
Type 1 diabetes mellitus is considered to be caused by
autoimmune destruction of the pancreatic beta cells, render-
ing the pancreas unable to synthesize and secrete suﬃcient
amounts of insulin. The nonobese diabetic (NOD) mouse
is an animal model with many features resembling human
type 1 diabetes, such as inﬁltrating immune cells (insulitis)
accompanied by spontaneous hyperglycaemia [9]. We have
shown that diabetic NOD mice have a higher sst expression
in the pancreatic islets as compared to normoglycemic NOD
mice [1]. The mechanism behind this receptor upregulation
in diabetic mice is not clear, but it may be either a conse-
quence of hyperglycemia or due to immune reactions in the
NOD mouse. To address this issue, we have performed both
in vivo syngeneic islet transplantations to diabetic as well as
normoglycemic NOD mice and cultured NOD mouse islets
in vitro at diﬀerent glucose concentrations and subsequently
evaluated islet sst expression. The rationale for this design is
that the in vitro system would provide an environment with
only an elevated glucose concentration, whilst in vivo after
islet transplantation both an inﬂuence from autoimmunity
and a diabetic milieu can be envisaged.2 Experimental Diabetes Research
2.MaterialsandMethods
2.1. Animals, Islet Isolation, and Culture. Inbred NOD mice
(Biomedical Center, Uppsala, Sweden), originally obtained
from the Clea Company, Aobadi, Japan, were used for this
study. The animals had free access to water and pelleted
food and were housed in a room with a 12-hour light/dark
cycle.Allexperimentswereapprovedbythelocalanimaleth-
ics committee at Uppsala University (Uppsala, Sweden) and
were in accordance with international guidelines (NIH pub-
lications 85–23). Blood glucose determinations (Medisense,
Waltham, MA, USA) were performed on blood samples tak-
en from the tail tip, and the weight of the animal was meas-
ured.
For islet isolation, male NOD mice (4–7 weeks of age)
were killed by cervical dislocation followed by resection of
the pancreas. Pancreatic islets were isolated by collagenase
digestion procedure [10], and islets were hand picked with
a braking pipette under stereomicroscope. Islets were precul-
tured 5–7 days in 4.5mL RPMI 1640 medium (Sigma-
Aldrich, St. Louis, Mo, USA) containing 11.1mM glucose,
supplemented with 10% fetal calf serum (FCS, vol/vol), ben-
zylpenicillin (100U/mL), and streptomycin (0.1mg/mL), in
an atmosphere of humidiﬁed air +5% CO2 before exper-
iments. Medium was changed every second day.
To investigate the eﬀect of glucose on sst expression in
vitro, groups of 100 pancreatic islets (n = 4) were cultured
in RPMI 1640 + 10% FCS supplemented with 5.6mM or
28.8mM glucose for three days (e.g., [11]). The medium was
changed on the second day.
2.2. Islet Transplantation beneath the Kidney Capsule. Af e -
male NOD mouse was considered diabetic when the non-
fasting blood glucose concentration exceeded 10mM and
served as recipient of grafted islets to diabetic mice, whereas
females with blood glucose below 10mM were designated as
normoglycemic. Normoglycemic (n = 6) and diabetic fe-
male (n = 6) NOD mice were anaesthetised with an intra-
peritoneal injection of 0.02mL/g body weight of Avertin (a
2.5% solution of 10g 97% 2,2,2-tribromoethanol (Sigma-
Aldrich) in 10mL 2-methyl-2-butanol (Kemila, Stockholm,
Sweden)). Cultured pancreatic islets, 200 islets per graft,
were collected in a braking pipette and implanted beneath
the left kidney capsule. It should be noted that the number
of implanted islets was on purpose chosen to be too low
to normalize the hyperglycemia of the diabetic mice. The
blood glucose levels were determined daily, and the animals
were killed after three days, and the graft-bearing kidney was
dissected free. The part of the kidney containing the islet
graftwasexcisedleavingamarginof1mm ofeachside ofthe
graft.
2.3. Staining with sst1–5 Antibodies. The production and
speciﬁcity of subtype-speciﬁc somatostatin receptor anti-
bodies has been described earlier [7, 12]. The grafts or cul-
tured islets were ﬁxed in 10% buﬀered formalin (Merck,
Darmstadt, Germany) for 24 hours at room temperature and
then changed to 70% ethanol and embedded in paraﬃn.
Sections, 5μm thick, were cut and attached to Polysine glass
slides (Menzel-Gl¨ aser, Braunschweig, Germany).
The specimens were single stained for the ﬁve sst recep-
tors [7]. The immune reaction was ampliﬁed by an avidin-
biotin complex coupled to alkaline phosphates (Vectastain
ABC-AP, Vector Laboratories Inc, Burlingame, Calif, USA)
and visualized with Vector Red (Vector Laboratories), as
substrate [7]. When the ssts-speciﬁc antibodies were prein-
cubated with the peptides used for immunization, the im-
munoreactivity for each receptor was blocked (data not
shown), [7]. Moreover, an extensive description of the gen-
eration, peptide speciﬁcity, and other characteristics of the
sst antibodies is given in [7].
2.4. Coexpression of sst1–5 and Islet Cells. To investigate the
coexpression of sst1−5 on the transplanted islet cells as well as
the cultured islets, we used the immunoﬂuorescence meth-
od described previously [7]. The transplants from normo-
glycemic female NOD mice and diabetic female NOD mice
or islets cultured in diﬀerent glucose concentrations were
collected, paraﬃn embedded, and stained for sst1−5 in a
cocktail with chicken anti-insulin (1:750, Immunsystem,
Uppsala, Sweden), chicken antiglucagon (1:400, a kind gift
from Professor Anders Larsson, Uppsala University, Upp-
sala, Sweden; raised against human glucagon (Novo Nor-
disk, Bagsvaerd, Denmark)), sheep antisomatostatin (1:25,
Guildhay, Guildford, UK), or sheep anti-PP (1:25, SeroTech,
Oxford, UK) as previously described [7] .T h ei m m u n er e a c -
tionwasvisualizedbyacocktailconsisting ofsecondaryanti-
bodies Cy3-conjugated donkey antirabbit IgG (1:100, Jack-
son ImmunoResearch, West Grove, Pa) and Cy2-conjugated
donkey antisheep IgG (1:100, Jackson ImmunoResearch)
or Cy2-conjugated donkey antichicken IgG (1:100, Jack-
son ImmunoResearch). The speciﬁcity of the commercially
employed antihormone antibodies was tested by using dif-
ferent dilutions of the antibodies as well as omitting the
primary antibodies. Concerning the generation, peptide
speciﬁcities, and characterization of antibodies against the
diﬀerent sst-receptors, an in-depth description can be found
in [7].
2.5. Morphological Evaluation. In the double ﬂuorescence
study, the kidney grafts or cultured islets were examined in
a Leica Leitz DMR ﬂuorescence microscope (Leica Microsys-
tems, Wetzlar, Germany) equipped with ﬁlters of 492nm
to 510nm for Cy2 (green) and 550nm to 570nm for Cy3
(red). Pictures from a Zeiss Axiocam camera (Carl Zeiss,
Oberkochen, Germany) of each transplants, using both ﬁl-
ters, were merged together with Adobe Photoshop 7.0 soft-
ware (Adobe, San Jose, Calif, USA), in which a yellow colour
indicated coexpression of the sst subtype with any of the four
islet hormones tested in this study. The results are expressed
as a percentage of ssts-positive cells in relation to the total
numberoftherespectiveisletcelltypeinaspeciﬁcpancreatic
islet.
2.6. Statistical Analysis. Data are presented as means ± SEM,
and groups of data were compared using Student’s t-test,Experimental Diabetes Research 3
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Figure 1: Blood glucose levels were determined every day for three
days in the transplanted NOD mice in the diabetic (n = 6) and
control (n = 6) groups.
where P < 0.05 was considered as statistically signiﬁcant. The
computer program used was SigmaStat 2.0 (SPSS Science,
Chicago, Ill, USA).
3. Results
3.1. Animals. The blood glucose concentrations for the
transplanted mice during three days are shown in Figure 1.
The value on day 0 was obtained immediately before the
operation and the day 3 value when the graft was removed.
As can be seen in the ﬁgure, the implanted number of islets
was not suﬃcient to cure the hyperglycemia, thus the mice
remained diabetic, and the implanted islets were exposed to
a diabetic state in vivo at least during the last two days.
NOD mouse islets grafted into normoglycemic female NOD
mice were used as control, and these mice remained normo-
glycemic throughout.
3.2.Coexpressionofsst1–5 withIsletsHormones. Toinvestigate
the inﬂuence of elevated glucose concentrations on the islet
sst expression pattern, grafts or cultured islets were double
stained with sst1−5 antibodies together with the islet hor-
mones insulin, glucagon, somatostatin, and PP.
In Figure 2, the quantitative analysis of the coexpression
of sst1−5 with insulin, that is, beta cells in in vitro cultured
islets (Figure 2(a)) or transplanted islets (Figure 2(b) is
shown. The sst3 expression in beta-cells was signiﬁcantly
upregulated in islets cultured at 28.8mM glucose, while the
sst5 expression was signiﬁcantly decreased as compared to
islets cultured at 5.6mM. No signiﬁcant diﬀerences in ex-
pression were observed for sst1, sst2, and sst4. In the in vivo
setting, the expression of all ssts remained unchanged except
for sst1 which was signiﬁcantly reduced in the islets removed
from diabetic animals.
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Figure 2: Quantitative analysis of the immunohistochemical
expression, using a double-labelling procedure, of ssts in beta
cells in isolated pancreatic islets cultured in diﬀerent glucose
concentrations ((a), n = 4) or in the transplanted islets grafts ((b),
n = 6). Bars represent the means ± SEM from the percentage of
cells positive for the given ssts. ∗P < 0.05, ∗∗P < 0.01 versus control
using Student’s unpaired t-test.
Figure 3 shows the distribution of insulin-positive cells
(green, Figures 3(a)–3(e)) and the merged picture of cells
coexpressing sst1−5 (yellow, Figures 3(f)–3(j)) in a represent-
ativesectionofatransplantedpancreaticislet fromadiabetic
NODmouse.SectionsoftransplantedNODmouseisletsun-
der the kidney capsule single stained for sst1−5 are shown
in Figures 3(k)–3(o). The grafts were harvested already on
day 3 with the intent that the process of so-called recurrence
of disease with immune cell inﬁltration should be minimal
[12, 13]. The kidney tissue was also weakly stained by the ssts
antibodies suggesting that renal tissue also expresses sst.
Therewasnosigniﬁcantdiﬀerenceinsst1–sst4 expression
onalphacellsbetweenisletsculturedat5.6mMand28.8mM
glucose, while sst5 was signiﬁcantly decreased when islets
were cultured at high glucose levels (Figure 4(a)). All ssts
remained unchanged on alpha cells from transplanted islets
(Figure 4(b)).4 Experimental Diabetes Research
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Figure 3: Syngeneic pancreatic islets in groups of 200 islets were transplanted beneath the kidney capsule, and the animal was sacriﬁced on
day 3 after transplantation. A representative graft in a transplanted diabetic NOD mouse stained for insulin (green, (a)–(e)) coexpressing
sst1−5 (yellow, (f)–(j)). (k)–(o) show a representative graft in transplanted diabetic NOD mice single stained with sst1−5-speciﬁc antibodies.
Bar = 50μm.Experimental Diabetes Research 5
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Figure 4: Quantitative analysis of the immunohistochemical
expression, using a double-labelling procedure, of ssts in alpha
cells in isolated pancreatic islets cultured in diﬀerent glucose
concentrations ((a), n = 4) or in the transplanted islets grafts ((b),
n = 6). Bars represent the means ± SEM from the percentage of
cells positive for the given ssts. ∗P < 0.05, ∗∗P < 0.01 versus control
using Student’s unpaired t-test.
Overall, the sst expression on delta cells in cultured islets
was fairly low (Figure 5(a)). However, the sst5 expression
was signiﬁcantly increased at the high glucose concentration.
The overall sst expression on delta cells in transplanted islets
was higher, but equal when comparing transplants from
normoglycemic and diabetic animals (Figure 5(b)).
On PP cells in islets cultured at 28.8mM glucose, an
increaseofsst1 andadecreaseinsst3 expressionwasobserved
(Figure 6(a)), while the expression of the other sst remained
unchanged. In transplanted islets, PP cells showed a decrease
in sst2 and an increase in sst4 expression, while the other ssts
remained unchanged (Figure 6(b)).
4. Discussion
We have previously shown that all sst subtypes are expressed
in rodent pancreatic islets, but on the expression varies
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Figure 5: Quantitative analysis of the immunohistochemical
expression, using a double-labelling procedure, of ssts in delta-
cells in isolated pancreatic islets cultured in diﬀerent glucose
concentrations ((a), n = 4) or in the transplanted islets grafts ((b),
n = 6). Bars represent the means ± SEM from the percentage of
cells positive for the given ssts. ∗P < 0.05, ∗∗P < 0.01 versus control
using Student’s unpaired t-test.
between the four major islet cell types [7]. Furthermore,
this sst expression was increased in diabetic compared to
normoglycemicNODmice,particularlyforsst2–sst5 [1].The
reason for this latter ﬁnding was not clear and the aim of
the present study was to investigate if the increased ssts
expression observed in pancreatic islets of diabetic NOD
micedependsonanelevatedglucoseconcentrationinvivoor
merelyreﬂectsaresponsetotheongoingimmunereactionin
the pancreas of the NOD mice.
NOD mouse pancreatic islets were cultured in vitro for
three days in media containing either 5.6mM glucose or
28.8mM glucose to elucidate the eﬀecto fanel evat edgl u c o s e
concentration without a putative inﬂuence of immune-
related factors present in vivo, for example, cytokines. In par-
allel precultured islets isolated from young normoglycemic
NOD mice were transplanted under the kidney capsule of6 Experimental Diabetes Research
Table 1: Summary of changes in islet cell sst expression in islets cultured at high glucose and in islet transplanted to hyperglycemic NOD
mice.
Cultured islets Transplanted islets
28mM glucose versus 5.6mM glucose Diabetic versus normoglycemic
Cell αβδ PP αβδ PP
sst1 → → →↑→↓→ →
sst2 →→→→→→→ ↓
sst3 → ↑ → ↓ →→→→
sst4 →→→→→→→ ↑
sst5 ↓ ↓ ↑ →→→→→
→ denotes no signiﬁcant change, ↓ denotes a decline in the fraction of cells expressing the sst, and ↑ denotes an increase in the fraction of cells expressing the
sst.
diabetic NOD mice. A suboptimal number of islets were im-
planted, which means that the diabetic animals remained
hyperglycaemic, and the grafted islets were exposed to a pro-
longed period of high glucose in vivo. The grafts were
removed after three days, before any marked signs of graft
destruction by invading immune cells following so-called re-
currence of disease [13, 14]. If a later time point after trans-
plantation had been selected, it is anticipated that the evolv-
ing graft destruction and further increasing blood glucose
concentrations would become confounding factors when
evaluating the current data.
The changes in sst expression observed after either cul-
ture at high glucose or after islet transplantation to diabetic
recipients are schematically summarized in Table 1.M o r e
alterations in islet cell expression of ssts were induced in the
in vitro setting compared to those observed in vivo following
islet transplantation. It cannot be excluded that the in vitro
environment allows more glucose-induced changes in sst ex-
pression to become manifest than in vivo, since compen-
satory extraislet mechanisms conveyed by nerves and blood
ﬂow may counteract such changes. In addition, the ambient
experimental glucose concentration (28.8mM) in vitro was
higher in comparison to the glucose concentration of the
transplanted diabetic mice (15–20mM). It is possible that
this diﬀerence in islet exposure to glucose had an impact on
changes in islet cell sst expression. Moreover, the changes ob-
served in vitro did not correspond to changes obtained in
vivo, which could argue in favour of the assumption that the
level of glucose is of importance.
The combined analysis of the in vivo and in vitro data
suggests that the alpha and delta cells were relatively unaf-
fected by the high-glucose conditions, whilst beta and PP
cells exhibited more dynamic changes. Concerning the spe-
ciﬁc sst, it was found that in vitro exposure to high glucose
aﬀected sst5 expression on alpha, beta, and delta cells. Sst5
activation is suggested to inhibit the insulin secretion in
rodents [8, 15–17]. Higher insulin levels are needed to meet
the demand of an elevated glucose concentration. It may
therefore be suggested that the decrease in sst5 expression
seen in this study is a downregulation of receptor expression
to avoid signalling which may inhibit the insulin secretion
from beta cells. Interestingly a similar decrease in beta cell
sst5 expression was found in the spontaneously diabetic
N O Dm i c e[ 1]. The eﬀect of the increased sst5 expression on
delta cells is unclear, but it might contribute to an autocrine-
mediated dampered secretion of somatostatin which would
promote insulin secretion.
The expression of sst3 was increased on beta cells in
isolated islets cultured at higher glucose concentrations. The
insulin-producing cell line MIN6 has previously been re-
ported to express sst3, and this was suggested to be related to
MAP kinase and c-fos signalling in inhibition of cell growth
by somatostatin [18]. An upregulation of sst3 by a high glu-
cose concentration could result in a restriction on beta-cell
proliferation promoted in a milieu of a high-functional de-
mand on the beta cells. Moreover, sst3 may also aﬀect sig-
nal transduction associated with adenyl cyclase activity [2],
which could be of relevance for beta-cell function since
cAMP is an important ampliﬁer of insulin secretion [19].
PP secretion is inhibited by somatostatin and by elevated
bloodglucoselevels[20].Athigherconcentrationsofglucose
in vitro, the sst1 expression was increased and sst3 expression
decreased on PP cells. It is possible that these combined
changes in expression of sst is part of the regulation of the
PP-cell response to high glucose. Further studies, however,
are needed to address this question.
5. Conclusion
In our earlier study in NOD mice, we reported a higher sst
expression in the pancreatic islets of diabetic mice as com-
pared to normoglycemic NOD mice [1]. The mechanism
behind this upregulation in diabetic mice was unclear, but
it may be either a consequence of hyperglycemia or due to
immune reactions in the NOD mouse. Our data from this
study indicates that hyperglycemia alone is not enough to
explain the changes observed in NOD mice in vivo. Either
immune-related mechanisms or other in vivo regulatory
mechanisms may counteract eﬀects of elevated glucose on
islet cell sst expression. Future studies should address the
mechanisms of the immune response for the changes in sst
expression in pancreatic islets observed in NOD mice with a
spontaneously developed diabetes.Experimental Diabetes Research 7
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Figure 6: Quantitative analysis of the immunohistochemical
expression, using a double-labelling procedure, of ssts in PP
cells in isolated pancreatic islets cultured in diﬀerent glucose
concentrations ((a), n = 4) or in the transplanted islets grafts ((b),
n = 6). Bars represent the means ± SEM from the percentage of
cells positive for the given ssts. ∗P < 0.05, ∗∗P < 0.01 versus control
using Student’s unpaired t-test.
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